The relationship of socioeconomic status (SES) with long-term outcomes in allogeneic hematopoietic cell transplantation (HCT) survivors has not been well described. We studied the association of SES with the outcomes of 283 consecutive allogeneic HCT recipients transplanted between 2003 and 2012 who had survived for at least 1 year in remission. Median annual household income was estimated using Census tract data and from ZIP code of residence. SES categories were determined by recursive partitioning analysis (low SES (o $51 000/year), N = 203; high SES (⩾ $51 000/year), N = 80). In multivariable analyses, low SES patients had higher risks of all-cause mortality (hazard ratio (HR) 1.98, P = 0.012) and non-relapse mortality (NRM) (HR 2.22, P = 0.028), but similar risks of relapse mortality (HR 1.01, P = 0.97) compared with high SES patients. A trend toward better survival and lower NRM for high SES patients with no chronic GVHD was observed; low SES patients without GVHD had similar survival as patients with chronic GVHD. In allogeneic HCT survivors who survive in remission for at least 1 year, SES is associated with long-term survival that is primarily mediated through higher risks of NRM. More research is needed to understand the mechanisms of health-care disparities and interventions to mitigate them.
INTRODUCTION
Allogeneic hematopoietic cell transplantation (HCT) survivors are at risk of long-term morbidity and mortality from late complications, such as late relapse of the primary disease, GVHD, immune deficiency, end-organ damage and development of secondary malignancies. [1] [2] [3] With advances in transplantation technology and supportive care, the number of long-term survivors after HCT continues to grow. [4] [5] [6] [7] [8] [9] Transplant survivors need life-long monitoring for late complications because many complications can be prevented or can be detected early and treated. 10, 11 Low socioeconomic status (SES) has been shown to be associated with health-care disparities including poor access and adverse outcomes in a variety of health conditions, including HCT. [12] [13] [14] [15] [16] [17] The most comprehensive analysis of the association of SES with HCT outcomes was reported by Baker et al.; 12 using data on 6207 unrelated-donor myeloablative HCT for acute and chronic leukemia and myelodysplastic syndromes, they showed that African-American (but not Asian or Hispanic) recipients had worse overall survival compared with Whites, and patients with median household incomes in the lowest quartile (o$34 700) had worse overall survival compared with patients with incomes in the highest quartile (4$56 300). However, the association of SES with outcomes in long-term HCT survivors has not been previously described.
Early post-transplant care is usually well coordinated through the transplant center. However, as patients transition back to their community providers, it is possible that patients with fewer resources and poor access to health care would be at higher risk of complications and mortality. Hence, we hypothesized that SES would be associated with survival in long-term survivors after allogeneic HCT. We describe the results of our retrospective cohort study, where we investigated the association of SES with overall mortality, non-relapse mortality (NRM) and relapse-related mortality in allogeneic HCT recipients who had survived for at least 1 year in remission.
METHODS

Patient characteristics
Our study included 283 consecutive allogeneic HCT recipients at the Cleveland Clinic's Blood & Marrow Transplant Program treated between 2003 and 2012 who had survived for at least 1 year in remission. Diagnoses were categorized into four groups: acute leukemia/myelodysplastic syndromes/myelofibrosis, lymphoma/CLL, CML and non-malignant disease. Patients received myeloablative or reduced-intensity conditioning regimens. Recipients of bone marrow, PBSCs and umbilical cord blood graft source and related and unrelated donor source were included in the analysis. The median follow-up of survivors was 51 months (range, 13-128 months). Our retrospective cohort study was approved and conducted under guidance from the Cleveland Clinic Institutional Review Board.
Annual household income was used to describe SES. Median annual household income was estimated using Census tract data and from ZIP code of residence at the time of transplantation, which is a well-described method for estimating SES in health services research.
12,18-23 SES categories were determined by recursive partitioning analysis and were categorized into low SES (o $51 000/year, N = 203) and high SES Outcomes and statistical analysis Endpoints were calculated from the date of transplantation. Primary endpoints were overall survival, NRM and relapse-related mortality. We evaluated the association of chronic GVHD and SES with clinical outcomes as a secondary objective.
Recursive partitioning analysis with a log-rank splitting method was used to identify groups based on median household income that best predict overall survival. Low and high SES groups were identified, as previously defined.
Patient and transplant characteristics were compared between patients with low and high SES using the Chi-square test or Wilcoxon rank sum test. Overall mortality was estimated using the Kaplan-Meier method and Abbreviations: CSA = cyclosporine; FK = tacrolimus; MDS = myelodysplastic syndromes; MMF = mycophenolate mofetil; MTX = methotrexate; SES = socioeconomic status.
compared using the log-rank test. NRM and relapse mortality were estimated using the cumulative incidence method and compared using the Gray test. Risk factors were identified with Cox proportional hazards analysis (overall mortality) or Fine and Gray regression (relapse mortality, NRM). Bootstrap analysis was used to identify multivariable risk factors. One thousand samples of size 283 were selected randomly with replacement from the data set, and stepwise analysis was done on these 1000 samples. SES was included in each model whether or not it was significant, otherwise variables that occurred in at least half of the 1000 models were considered significant. In addition to SES, variables considered in multivariable analysis included age, gender, race/ethnicity, diagnosis category, disease risk, HCT Comorbidity Index score, Karnofsky performance status, number of prior chemotherapy regimens, prior radiation therapy, graft source, time from diagnosis to transplant, donor and graft source, HLA-match, conditioning regimen intensity and CMV status. Analyses were conducted using SAS software (version 9.4). All P-values are two-sided and a P-value of o0.05 was considered as significant.
RESULTS
Patient, disease and transplant characteristics by SES category Table 1 describes patient, disease and transplant characteristics based on SES category. Low SES patients were more likely to be of non-White race (10 vs 1%) and have Karnofsky performance status ⩽70 (6 vs 0%), otherwise there were no significant differences between the two cohorts, including age, gender, diagnosis, prior treatment, disease status, HCT Comorbidity Index scores, donor source, graft source and conditioning regimen intensity. The majority of patients in both cohorts had an underlying diagnosis of acute leukemia, myelodsyplastic syndromes or myelofibrosis and had received a myeloablative conditioning regimen. The median follow-up for survivors was 49 months for low SES patients and 54 months for high SES patients.
Outcomes by SES category In univariate analysis, low SES patients had worse 5-year overall survival (64%, 95% confidence interval (CI) 56-71%) compared with high SES patients (77%, 95% CI 67-88%) (P = 0.018, Figure 1a ). Relapse mortality was comparable between the two groups; 5-year incidence of relapse mortality was 15% (95% CI 10-20%) in low SES patients vs 12% (95% CI 5-21%) in high SES patients (P = 0.39, Figure 1b ). However, low SES patients had significantly worse NRM; 5-year incidence of NRM was 22% (95% CI 16-29%) in low SES patients compared with 11% (95% CI 5-21%) in high SES patients (P = 0.038, Figure 1c) . In multivariable analyses that adjusted for other patient-, disease-and transplant-related characteristics, patients with low SES had significantly higher risks of overall mortality (hazard ratio 1.98, 95% CI 1.16-3.37, P = 0.012) and NRM (hazard ratio 2.22, 95% CI 1.09-4.50, P = 0.028) compared with high SES patients, but similar risks of relapse mortality (hazard ratio 1.01, 95% CI 0.44-2.34, P = 0.97) ( Table 2 ).
Association of GVHD and outcomes by SES category Chronic GVHD can be associated with late morbidity and mortality in allogeneic HCT recipients and patients with this complication require coordinated rigorous follow-up for its management. In line with our overall hypothesis, we postulated that chronic GVHD may exacerbate health-care disparities in long-term transplantation outcomes. Hence, we conducted an exploratory analysis to evaluate the association of chronic GVHD and clinical outcomes by SES category. The 1-year incidence of chronic GVHD was 49% (95% Cl 42-56%) in low SES patients compared with 45% (95% Cl 34-57%) in high SES patients (P = 0.57). There was a trend toward lower overall mortality among patients with high SES and no history of chronic GVHD. The overall survival rates at 5 years were 86% (95% CI 73-98%) in high SES patients with no chronic GHVD, 68% (95% CI 51-84%) in high SES patients with chronic GVHD, 67% (95% CI 57-77%) in low SES patients with no chronic GVHD and 60% (95% CI 49-71%) in low SES patients with chronic GVHD (P = 0.06) (Figure 2 ). The corresponding 5-year cumulative incidence of NRM for the four groups was 5% (95% CI 1-15%), 17% (95% CI 6-34%), 18% (95% CI 11-28%) and 26% (17-36%), respectively (P = 0.63). We did not observe a difference in relapse-related mortality in this analysis, with 5-year cumulative incidences of 10% (95% CI 2-24%), 15% (95% CI 5-29%), 15% (95% CI 8-23%) and 14% (95% CI 8-23%), respectively. Because of the small numbers of patients in some categories, we were not able to pursue multivariable analyses to further evaluate the association of SES and chronic GVHD or to examine the impact of severity of chronic GVHD on outcomes. 
Causes of death
In low SES group, 70 out of 203 patients died, 27 (39%) deaths were due to disease relapse, while 43 (61%) deaths were related to non-relapse-related causes. Infection (20%), organ toxicity (17%) and chronic GVHD (11%) were the common causes of NRM. In high SES group, 17 out of 80 patients died, 8 (47%) were due to disease relapse and 9 (53%) were related to other causes. Organ toxicity (18%), chronic GVHD (18%) and infection (12%) remained as the common causes of NRM.
DISCUSSION
Our study shows the association of SES with long-term outcomes in allogeneic HCT survivors. Patients with low SES had higher mortality compared with patients with high SES, and this difference in survival was primarily mediated through higher rates of NRM. The risks of relapse-related mortality did not differ by SES. Our analysis adds to the growing literature on health-care disparities in HCT recipients and provides information on the interaction of SES with outcomes in a population of patients (longterm HCT survivors) that has not been well described previously. Early post-transplant care (through the first 3-6 months) tends to be well coordinated through the transplant center with robust networks for social and medical support. Health-care disparity factors may have a prominent role in patient health status as they transition and receive long-term health care in their local communities. Health-care disparities constitute a complex construct of sociological, demographic and behavioral factors and SES is one validated method for its evaluation. SES serves as a surrogate for several factors such as insurance status, including quality of health-care coverage, education status and health literacy, employment, and ability to travel to a health-care facility, especially if the transplant center is some distance away from the patient's residence. All these factors can impact access to health care and may have an accentuated effect on outcomes when the patient's care is no longer being closely coordinated through the transplant center. In our experience, the difference in survival was mainly driven by higher risks of NRM between the two cohorts. Relapse is determined by the biology of underlying disease and may not be significantly affected by socio-demographic factors.
Although we were not able to comprehensively evaluate the association of chronic GVHD with SES and outcomes, our exploratory analyses revealed a few interesting trends. Contrary to our hypothesis that SES would accentuate health-care disparities in patients with chronic GVHD, overall mortality, NRM or relapse mortality appeared to be comparable among low and high SES patients with this post-transplant complication. We speculate that because of the severe morbidity that can be associated with chronic GVHD, patients try to get the care they need to control symptoms and disease manifestations irrespective of their SES. SES appeared to have the greatest impact in patients without chronic GVHD, although this difference was not statistically significant, likely because of the lack of power owing to the small number of patients in our analysis. As noted above, we could not evaluate the impact of chronic GVHD severity on outcomes by SES and we were not able to perform robust multivariable analyses to further evaluate the association of GVHD with mortality. However, if confirmed by larger analyses, we may be able to identify a subgroup of patients who may benefit the most from targeted interventions.
Our observations from a single-center study need to be confirmed in a larger multi-center cohort of HCT survivors. In the meantime, our findings have some immediate implications for clinical practice. First, we highlight a patient group that is particularly vulnerable to adverse outcomes following allogeneic transplantation. Among their long-term survivors, transplant centers can consider prioritizing and directing resources and programs to this population to ensure that timely access to care can be facilitated for these patients, either at the transplant center or through a local community provider. Policy makers and payers may also be able to improve outcomes for patients with low SES by considering policies that allow timely access to adequate health care. Examples include adequate coverage for evaluations needed for preventive care and coverage for travel/transportation to the transplant center or a local provider. As the transplant community considers guidelines for long-term follow-up and prevention of late complications, we may need to call out issues specific to these underserved populations.
Some limitations of our study have to be considered. We did not use the actual household income for patients. However, median household income based on ZIP code of residence and Census tract data is a well-validated method for evaluating SES in health services research. 12, [18] [19] [20] [21] [22] [23] The two categories for SES were determined based on recursive partitioning analysis and, hence, were dependent on the characteristics of our cohort and would need to be validated in larger studies. Given our overall sample size, we were not able to establish a validation cohort for our study. As noted above, our study lays the foundation for further investigation in this area through multi-center or registry cohorts. Finally, we were only able to evaluate patients who received a transplant and cannot address the role of SES in disparities that determine whether a patient undergoes the transplant procedure. Access to HCT continues to be an important area that needs to be addressed with SES likely having an important role.
In conclusion, our study highlights the association of low SES and inferior overall survival among allogeneic HCT recipients who survive in remission for at least 1 year after transplantation. This disparity in survival is primarily mediated through a higher risk of NRM, suggesting a role for barriers to access to health care in this underserved population as they survive long-term post-transplant. More research is needed to understand the mechanisms of these health-care disparities and to identify interventions to mitigate them.
